Newsdeck

COVID-19

South Africa’s Biovac in talks to manufacture COVID-19 vaccines

Covid-19 Vaccine trial. (Photo: Wits University/Spotlight)
By Reuters
14 Oct 2020 2

CAPE TOWN, Oct 14 (Reuters) - A South African company part-owned by the government is in talks with the global COVID-19 vaccine distribution scheme and pharmaceutical companies to produce some of the vaccines the country needs to protect itself against the disease.

The Biovac Institute, a Cape Town-based joint venture between the government and private sector, could produce up to 30 million doses of COVID-19 vaccines per year, depending on the technology involved, Chief Executive Morena Makhoana told Reuters.

Depending on whether the vaccines require a one- or two-dose regimen, that could be enough for a quarter or half of South Africa’s population.

“We need to look at who is likely to get to the finishing line and who has the technological fit,” Makhoana said, when asked which vaccine candidate Biovac might partner with. “Discussions are happening and we are fairly confident that … we will be able to clinch a deal.”

The Coalition for Epidemic Preparedness Innovations (CEPI), the foundation that co-leads the COVAX scheme alongside the World Health Organization and vaccines alliance GAVI, has identified Biovac as a potential drug product manufacturer but has not signed an agreement yet, a CEPI spokesman said.

Drug product manufacturing typically includes steps like vaccine formulation, filling and finishing of vials, labelling and packaging, he said.

The COVAX scheme aims to deliver 2 billion doses of COVID-19 vaccine by the end of 2021. CEPI is reserving capacity with vaccine manufacturers worldwide so that goal can be met.

South Africa has submitted a non-binding confirmation of intent to participate in COVAX.

Makhoana said Biovac could not make “live virus” vaccines at this stage, precluding some vaccines being trailed in South Africa in partnership with Oxford University and Johnson & Johnson. He declined to name the companies Biovac was speaking to.

The Department of Science and Innovation, the ministry that manages the government’s stake in Biovac, supports its ambitions because it wants to stimulate local manufacturing and limit the impact of vaccine procurement on the country’s balance of payments, Director-General Phil Mjwara said.

Currently South Africa’s government buys about 95% of the vaccines supplied annually by Biovac, covering diseases such as tuberculosis, cervical cancer and influenza, with the rest sold to countries in the rest of Africa.

In the past Biovac has partnered with companies like Pfizer and Sanofi.

(Reporting by Wendell Roelf and Alexander Winning Editing by Tim Cocks and Elaine Hardcastle)

Gallery

"Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]"

Comments - share your knowledge and experience

Please note you must be a Maverick Insider to comment. Sign up here or sign in if you are already an Insider.

Everybody has an opinion but not everyone has the knowledge and the experience to contribute meaningfully to a discussion. That’s what we want from our members. Help us learn with your expertise and insights on articles that we publish. We encourage different, respectful viewpoints to further our understanding of the world. View our comments policy here.

All Comments 2

  • My comments might be synical and full of scepticism but given all the corruption in situ, perhaps this report should also reflect some due diligence to give readers some sense of reality. SA Biovac participating in manufacturing the vaccine would be great especially when transparency about cost to the taxpayer, trustworthy tender processes, Distribution, records of consumption for SA and potentially transparency in exports to Sub-Sahara countries and beyond will be enforced.
    If not it could end up being another Transnet+ saga.

  • Please peer review 3 community comments before your comment can be posted